Bristol-Myers Squibb
Bristol-Myers Squibb Company, commonly referred to as BMS, is a leading global biopharmaceutical firm headquartered in the United States. Founded in 1887, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative medicines in oncology, immunology, and cardiovascular disease. BMS is renowned for its groundbreaking therapies, such as Opdivo and Eliquis, which have transformed treatment paradigms and improved patient outcomes. The company’s commitment to research and development has positioned it as a key player in the pharmaceutical industry, consistently achieving significant milestones, including numerous FDA approvals and recognitions for its contributions to healthcare. With a robust pipeline and a dedication to addressing unmet medical needs, Bristol-Myers Squibb continues to solidify its market position as a pioneer in biopharmaceutical innovation.
DitchCarbon Score
How does Bristol-Myers Squibb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bristol-Myers Squibb's score of 69 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bristol-Myers Squibb's reported carbon emissions
In 2023, Bristol-Myers Squibb (BMS) reported total greenhouse gas emissions of approximately 2,117,929,000 kg CO2e globally. This includes 208,535,000 kg CO2e from Scope 1 (direct emissions) and 158,447,000 kg CO2e from Scope 2 (indirect emissions). Notably, BMS has not disclosed any Scope 3 emissions data for this year. BMS has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across all scopes by 2050. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 54.6% by 2033, using 2022 as the base year. Additionally, BMS plans to reduce Scope 3 emissions from fuel and energy-related activities by the same percentage within the same timeframe. By 2050, BMS aims to achieve a 90% reduction in both Scope 1 and 2 emissions, as well as Scope 3 emissions. BMS is also committed to ensuring that 75% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028. This commitment reflects BMS's dedication to addressing emissions throughout its value chain. Overall, BMS's climate strategy aligns with industry standards and demonstrates a proactive approach to mitigating climate change impacts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bristol-Myers Squibb is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
